Jupiter Neurosciences shares rise 2.03% after-hours as CEO and President discuss longevity and brain health initiatives.

jueves, 21 de agosto de 2025, 4:26 pm ET1 min de lectura
JUNS--
Jupiter Neurosciences, Inc. rose 2.03% in after-hours trading, with the company's CEO and President discussing the company's efforts to address longevity and brain health with JOTROL and its new direct-to-consumer product line, Nugevia. Jupiter Neurosciences is a clinical-stage pharmaceutical company developing JOTROL, an enhanced orally administered resveratrol formulation known for its antioxidant and anti-inflammatory effects.

Jupiter Neurosciences shares rise 2.03% after-hours as CEO and President discuss longevity and brain health initiatives.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios